Coming Soon·Opens soon·Synced from source July 6, 2026
Health Equity Innovation Award: Enhance Equity Funding Opportunity (U01) Clinical Trials Not Allowed
Food and Drug Administration
Posted
Oct 23, 2025
Amount
$1,000,000
Closes
No deadline published by the funder
Last verified
Jul 6, 2026
At a glance
This funding opportunity is offered by Food and Drug Administration. Awards are up to $1,000,000.
Classification and identifiers
- Solicitation number
- FOR-FD-25-011
- Assistance listing (CFDA)
- 93.103
Amount
$1,000,000
Who can apply
State governmentsOpen to allSchool districtsFor-profitsSmall businessTribal organizations
About this opportunity
The purpose of this notice of funding opportunity (NOFO) is to fund innovative research that will strengthen and advance minority health and health equity objectives. Areas of interest include: Proposals that focus on advancing equity in clinical trials by supporting efforts to advance diversity in clinical trials, equitable data efforts by increasing data available on diverse groups including, but not limited to, ethnicity, race, age, disability and geography, and equity of voices by increasing understanding of diverse patient perspectives, preferences, and unmet needs.
Related opportunities
- FDA OMHHE Health Equity Innovation Award: Enhance Equity Funding Opportunity (U01) Clinical Trials Not AllowedFood and Drug AdministrationUp to $1.0M
- Educational Funding Opportunity: Expanding education on skin lightening products (U01) Clinical Trials Not AllowedFood and Drug AdministrationUp to $250K
- Research Opportunities in Cancer Epidemiology Cohort Studies (U01 Clinical Trial Not Allowed)National Institutes of HealthCloses Jul 2029
- Forecast to Publish a Funding Opportunity Announcement for Cancer Epidemiology Cohorts: Building the Next Generation of Research Cohorts (U01 Clinical Trial Not Allowed)National Institutes of Health
- OMHHE Educational Funding Opportunity: Expanding education on skin lightening products (U01) Clinical Trials Not AllowedFood and Drug AdministrationUp to $250K
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)National Institutes of HealthCloses Nov 2026Up to $150K
Finding similar opportunities...